HCW9302 for alopecia areata
phase 1drug program · high · Sat Aug 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Treat alopecia areata by using an interleukin-2-based fusion molecule designed to differentially expand regulatory T cells and rebalance immune activity.
Phase 1 open-label, multi-center, competitive-enrollment, dose-escalation clinical study of HCW9302 in subjects with alopecia areata; HCW9302 is described as an IL-2-based fusion molecule.
Phase 1 clinical trial listed for HCW9302 in alopecia areata.
Preclinical publication reports HCW9302 differentially promotes regulatory T cell expansion to treat atherosclerosis in mice; no alopecia areata clinical results were supplied.
HCW11-006
undiscloseddrug program · low
Undisclosed pipeline program.
Not specified in the supplied material.
Listed in the company pipeline.
HCW11-018b tissue factor-targeted T-cell engager
preclinicaldrug program · high
Improve bispecific T-cell engager therapy for solid tumors by overcoming immunosuppression and promoting CD8+ T-cell activation and tumor infiltration.
TRBC-platform tetravalent heterodimeric T-cell engager containing a tissue-factor-targeting antibody, anti-CD3 single-chain antibody, IL-15/IL-15Ralpha activity, and a TGF-beta trap; tested in vitro, mouse tumor models, PDX models, and non-human primate tolerability studies.
Reported in 2026 AACR abstract as being in IND-enabling studies for clinical development against solid tumors.
HCW11-018b induced antigen-specific tumor killing, increased T-cell activation markers, promoted tumor infiltration, enhanced cytotoxicity against cancer cells, reduced metastasis from the primary site, showed potency in a pancreatic cancer PDX model, and was well tolerated in mice and non-human primates with subcutaneous administration.
HCW11-018b tissue-factor-targeted tetravalent T-cell engager
preclinicaldrug program · high
Improve bispecific T-cell engager therapy for solid tumors by promoting T-cell activation, tumor infiltration, and resistance to immunosuppression.
TRBC-platform tetravalent heterodimeric T-cell engager targeting tissue factor and CD3, with IL-15R alpha, soluble IL-15, and a dimeric soluble TGF-betaRII trap.
Reported in 2026 AACR abstract as being in IND-enabling studies for clinical development against solid tumors.
In vitro and mouse studies reported robust antigen-specific tumor killing, increased STAT5 phosphorylation and activation markers, tumor infiltration of human T cells, reduced metastasis from the primary site, activity in a patient-derived pancreatic cancer model, and tolerability in mice and non-human primates after subcutaneous administration.
HCW11-040
undiscloseddrug program · low
Undisclosed pipeline program.
Not specified in the supplied material.
Listed in the company pipeline.
HCW9201
undiscloseddrug program · low
Undisclosed pipeline program.
Not specified in the supplied material.
Listed in the company pipeline.
HCW9206 cytokine-fusion scaffold for CAR T cell manufacturing
preclinicalresearch program · high
Generate highly functional CAR T cells enriched in long-lived T memory stem cells to improve persistence and efficacy in infectious disease and cancer models.
Protein scaffold linking IL-7, an IL-15/IL-15 receptor alpha complex, and IL-21, used to generate CAR T cells without alpha-CD3/CD28 activation.
2026 Science Advances publication describing HCW9206-generated CAR T cells in HIV and leukemia mouse models.
HCW9206-generated CAR T cells were enriched for T memory stem cells, suppressed viremia more effectively than alpha-CD3/CD28-generated anti-HIV duoCAR T cells, and cleared leukemia rechallenge in a xenograft model.
HCW9206 cytokine-fusion scaffold for CAR T manufacturing
preclinicalresearch program · high
Generate more persistent and functional CAR T cells enriched in long-lived T memory stem cells for infectious disease and cancer applications.
IL-7/IL-15/IL-21 cytokine-fusion scaffold used to generate CAR T cells without anti-CD3/CD28 activation; tested in humanized mouse HIV infection and xenograft leukemia mouse models.
2026 Science Advances publication describing HCW9206-generated CAR T cells in HIV and leukemia models.
HCW9206-generated CAR T cells were enriched in TSCM cells above 50%, suppressed HIV viremia more effectively than conventionally generated CAR T cells, and showed recall proliferation plus complete clearance of leukemia rechallenge in a mouse model.
HCW9218 bifunctional TGF-beta trap/IL-15 immunotherapy
phase 1drug program · high
Boost antitumor immune responses and reduce therapy-induced senescent cells by combining IL-15 stimulation with TGF-beta blockade.
Bifunctional TGF-betaRII/IL-15 protein complex evaluated in murine melanoma and breast cancer models, combinations with immune-checkpoint inhibitors, and a Phase 1 dose-escalation trial in patients with chemo-refractory or relapsed solid tumors.
Safety and immune profiling performed in a Phase 1 dose-escalation trial in patients with chemo-refractory or relapsed solid tumors.
Preclinical results indicate localization to tumor-draining lymph nodes and tumors after subcutaneous administration, TGF-beta neutralization, expansion of progenitor exhausted CD8+ T cells, increased effector cells, and synergy with immune-checkpoint inhibitors. Supplied publication title also reports chemotherapy augmentation via NK-cell-mediated reduction of therapy-induced senescent cells.
HCW9218 TGF-beta trap/IL-15 immunotherapeutic complex
phase 1drug program · high
Boost anti-tumor immunity and reduce senescent cells associated with chemotherapy-induced or senescence-associated inflammatory states.
Bifunctional TGF-betaRII/IL-15 protein complex designed to neutralize TGF-beta and stimulate IL-15 signaling in immune cells.
Safety and immune profiling performed in patients with chemo-refractory or relapsed solid tumors in a Phase 1 dose-escalation trial.
Preclinical studies reported localization to tumor-draining lymph nodes and tumors, TGF-beta neutralization, expansion of progenitor exhausted CD8+ T cells, increased effector infiltration, synergy with checkpoint inhibitors, and reduction of therapy-induced senescent cells in mouse models.
Memory-like NK cell fusion-protein program
preclinicalresearch program · medium
Generate memory-like natural killer cells for cell therapy.
Prime-and-expand strategy using multifunctional fusion proteins to generate memory-like NK cells.
2024 publication describing the prime-and-expand strategy.
Memory-like NK cell prime-and-expand fusion protein program
preclinicalresearch program · medium
Generate memory-like natural killer cells for cell therapy and cancer immunotherapy.
Prime-and-expand strategy using multifunctional fusion proteins, including fusion protein complexes combining IL-12, IL-15, and IL-18 signaling.
2024 publication on a prime-and-expand strategy using multifunctional fusion proteins to generate memory-like NK cells for cell therapy.
Supplied publication titles report generation of memory-like NK cells and induction of memory-like NK cells for cancer immunotherapy; detailed results were not supplied.
TOBI cytokine-based fusion immunotherapy platform
exploratoryplatform · medium
Create multi-domain cytokine-based fusion molecules intended to rebalance or rejuvenate immune cells for autoimmune disease, cancer, and senescence-associated dysplasia.
Proprietary platform for engineering multifunctional cytokine-based fusion immunotherapies.
Listed by the company as a proprietary platform supporting its pipeline of fusion molecules.
TOBI cytokine-fusion platform
undisclosedplatform · medium
Create multi-domain cytokine-based fusion molecules intended to rebalance or rejuvenate immune cells for autoimmune diseases, cancer, and senescence-associated dysplasia.
Proprietary fusion immunotherapeutic platform for cytokine-based immune-cell modulation.
Listed by the company as one of its proprietary platforms.
TRBC immune-cell-targeting fusion platform
undisclosedplatform · high
Create immune-cell-targeting fusion molecules, including multi-component T-cell engagers for cancer therapy.
Proprietary TRBC platform used to construct heterodimeric fusion proteins such as HCW11-018b.
Used to construct HCW11-018b, a tetravalent heterodimeric T-cell engager reported in a 2026 AACR abstract and described as in IND-enabling studies.
In HCW11-018b, the platform enabled addition of TGF-beta trap and IL-15 components to a BiTE-like format, with preclinical activity in solid tumor models.
